The approval is based on results from the KEYNOTE-905/EV-303 trial, conducted in partnership with Pfizer and Astellas.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv ...

Merck MRK announced that the European Commission has approved its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), and ...

In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease ...

Japanese drugmaker Astellas Pharma has won European Commission (EC) approval for Padcev (enfortumab vedotin) in combination ...

The FDA approved the combination for patients with locally advanced or metastatic urothelial carcinoma who are ineligible for treatment with cisplatin-based chemotherapy. The Food and Drug ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced positive topline results from the Phase 3 EV-303 clinical trial (also known ...

The U.S. Food and Drug Administration has approved Pfizer's Padcev (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, as a perioperative neoadjuvant treatment and postcystectomy ...

NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") today announced that on December 15, 2023 the U.S. Food and ...

Patients with previously untreated locally advanced or metastatic urothelial carcinoma experienced favorable progression-free survival, overall survival and objective response rates when treated with ...

The standing ovation for Keytruda and Padcev in metastatic bladder cancer at the 2023 European Society for Medical Oncology (ESMO) Congress still echoes, and, now, the pair from Merck & Co., Pfizer ...

Even a pandemic can’t slow Seattle Genetics and Astellas' new bladder cancer treatment Padcev down—and analysts are jacking up their sales estimates for the drug as a result. In its first quarter on ...